

# You Are Cordially Invited to Attend a Professional Lecture

This promotional program is intended to educate healthcare practitioners on

## A Clinical Overview of

**Vraylar**<sup>®</sup>  
(cariprazine) capsules  
1.5mg•3mg•4.5mg•6mg

PRESENTED VIA WEBCAST BY:

**Susan Moore, FNP**

Wytheville, VA

*Sponsored by Allergan*

**Wednesday, May 20, 2020 at 6:30 PM**

**Login: <http://medforce.adobeconnect.com/virtualseakerprogram86167/>**

**Dial-in Information:**

**Phone number: (877) 885-3221 • Passcode: 5580611**

**Please RSVP for this program by using the following link:**

**<http://www.medforcereg.net/SALG86167>**

**If you cannot join us for this event, please go to <https://www.vraylarlive.com> to register for another event.**

MedForce can accept RSVPs from HCPs. Call 888-335-8430. Please reference Meeting ID 86167.

For questions contact your Allergan Representative Nicole Dell'Aquila Phone:(609) 221-7535

This promotional event is brought to you by Allergan and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of Allergan and the information being presented is consistent with FDA guidelines.

This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is Allergan's policy to include only those HCPs involved in patient care consistent with our product indication(s).

The cost of meals and refreshments provided to the U.S. HCPs may be subject to public disclosure. Allergan's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. Allergan abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from Allergan. Please comply with applicable law.

Attendance might be limited to Company policy on product indication and promotion.

### INDICATIONS AND USAGE

VRAYLAR is an atypical antipsychotic indicated for the:

- Treatment of schizophrenia in adults
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults
- Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults

### IMPORTANT SAFETY INFORMATION

**WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS**

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for treatment of patients with dementia-related psychosis.
- Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Safety and effectiveness of VRAYLAR have not been established in pediatric patients.

**Contraindication:** VRAYLAR is contraindicated in patients with known hypersensitivity. Reactions have included rash, pruritus, urticaria, and events suggestive of angioedema.

**Please see additional Important Safety Information on following page and accompanying full Prescribing Information, including Boxed Warnings.**

